SCHEMBL422261

SCHEMBL422261

O=C(O)c1ccc(C23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.56
ALDH1A1 P00352 2/20 0.55
LMNA P02545 1/20 0.55
SERPINE1 P05121 1/20 0.53
RARA P10276 3/20 0.52
RARB P10826 3/20 0.52
RARG P13631 3/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
EPHX2 P34913 2/20 0.51
RAB9A P51151 1/20 0.51
HIF1A Q16665 3/20 0.51
EPAS1 Q99814 2/20 0.51
THRB P10828 1/20 0.50
RECQL P46063 1/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
GFER P55789 1/20 0.50
NR2E1 Q9Y466 1/20 0.50
STS P08842 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2710121 0.98 NPC1 (0.54) NPC1ALDH1A1LMNASERPINE1RARA
SCHEMBL25309350 0.92 TSHR (0.50) NPC1ALDH1A1LMNASERPINE1RARA
SCHEMBL22453447 0.90 NPC1 (0.59) NPC1ALDH1A1LMNASERPINE1RARA
SCHEMBL19362904 0.90 MEN1 (0.55) NPC1ALDH1A1LMNASERPINE1RARA
SCHEMBL22453210 0.90 NPC1 (0.59) NPC1ALDH1A1LMNASERPINE1RARA
SCHEMBL2745792 0.89 PGR (0.50) NPC1ALDH1A1LMNARARARARB
SCHEMBL5084601 0.85 TSHR (0.46) NPC1ALDH1A1SERPINE1RARARARB
SCHEMBL10011879 0.85 NPC1 (0.56) NPC1ALDH1A1LMNASERPINE1MEN1
SCHEMBL12942421 0.84 TSHR (0.50) NPC1ALDH1A1SERPINE1MEN1KMT2A
SCHEMBL25196882 0.84 RARA (0.56) NPC1LMNASERPINE1RARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002504529-A 2002-02-12 JP claimed
EP-1060160-A2 DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-12-20 EP claimed
WO-1999043636-A2 DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-09-02 WO claimed
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
EP-2478981-B1 SILVER-(CONJUGATED COMPOUND) COMPLEX SUMITOMO CHEMICAL CO (JP) 2020-12-23 EP disclosed
US-9704612-B2 Composition of silver-conjugated compound composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-11 US disclosed
US-9412487-B2 Silver-(conjugated compound) composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-09 US disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
US-20140001422-A1 COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-02 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2478981-A1 SILVER-(CONJUGATED COMPOUND) COMPLEX Sumitomo Chemical Co., Ltd (JP) 2012-07-25 EP disclosed
US-20120168693-A1 SILVER-(CONJUGATED COMPOUND) COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-05 US disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed
US-20070078256-A1 Prepolymers, prepolymer compositions, high-molecular-weight polymers with pore structure, and dielectric films DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 NPC1 893/4885ALDH1A1 1450/4885LMNA 482/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 NPC1 893/4885ALDH1A1 1450/4885LMNA 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.